person · Reporting owner
Claremount VII Associates, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oscar Health, Inc.OSCR · Entity 3582 | Director · 10% owner | November 20, 2024 | November 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oscar Health, Inc.
Report date November 20, 2024 · Filed November 22, 2024
Jointly reported with Thrive Partners VII Growth GP, LLC, Thrive Capital Partners VII Growth, L.P., Thrive Partners VII GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,243,617 |
Reported balance
After 2024-11-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-11-20 · Purchase · Acquired 88,395 · Balance 6,243,617 F1: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 6,343,617 |
Reported balance
After 2024-11-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-11-21 · Purchase · Acquired 100,000 · Balance 6,343,617 F3: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII.
F2: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
F3: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2024 Filed Nov 22, 2024 16:33 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 100,000 | $16.86 | $1,685,980.00 |
DisclosureSEC source: 0000950170-24-130257 · ownership.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,343,617 F3 · shares: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F3 · price: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 98,809 shares purchased by Thrive VII Growth and (ii) 1,191 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.60 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,268,097 shares are held directly by Thrive VII Growth and 75,520 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 16:33 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 88,395 | $16.97 | $1,499,700.73 |
DisclosureSEC source: 0000950170-24-130257 · ownership.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,243,617 F1 · shares: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F1 · price: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 87,343 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,052 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.92 to $17.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,169,288 shares are held directly by Thrive VII Growth and 74,329 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 17:02 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 185,790 | $15.97 | $2,966,155.93 |
DisclosureSEC source: 0000950170-24-128068 · ownership.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,155,222 F3 · shares: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F3 · price: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 183,567 shares purchased by Thrive VII Growth and (ii) 2,223 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.87 to $16.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 6,081,945 shares are held directly by Thrive VII Growth and 73,277 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 17:02 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 158,732 | $15.61 | $2,478,187.48 |
DisclosureSEC source: 0000950170-24-128068 · ownership.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,969,432 F1 · shares: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F1 · price: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 156,855 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,877 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.87 to $15.865, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,898,378 shares are held directly by Thrive VII Growth and 71,054 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 13, 2024 Filed Nov 13, 2024 21:11 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 358,619 | $13.74 | $4,926,313.34 |
DisclosureSEC source: 0000950170-24-126662 · ownership.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,810,700 F4 · shares: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177shares are held directly by Claremount VII. F4 · price: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 354,349 shares purchased by Thrive VII Growth and (ii) 4,270 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.435 to $14.21, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,741,523 shares are held directly by Thrive VII Growth and 69,177shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 21:11 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 420,819 | $13.68 | $5,755,625.63 |
DisclosureSEC source: 0000950170-24-126662 · ownership.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,452,081 F3 · shares: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F3 · price: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 415,808 shares purchased by Thrive VII Growth and (ii) 5,011 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.45 to $14.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 5,387,174 shares are held directly by Thrive VII Growth and 64,907 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:11 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 276,040 | $13.58 | $3,748,043.52 |
DisclosureSEC source: 0000950170-24-126662 · ownership.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,031,262 F1 · shares: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F1 · price: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 272,754 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,286 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.205 to $13.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,971,366 shares are held directly by Thrive VII Growth and 59,896 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 16:05 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Grant7.25% Convertible Senior Notes · Derivative | 417,000 | $417,000.00 Strike: $8.32 | $173,889,000,000.00 |
DisclosureSEC source: 0000899243-22-005007 · doc4.xml · derivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Claremount VII Associates, L.P. Disclosed balance after: 417,000 Underlying: Class A Common Stock · 50,111 shares Expires not disclosed F1 · derivative.exercise_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.exercise_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F1 · derivative.expiration_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.expiration_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F4 · ownership.nature: Securities held directly by Claremount VII Associates, L.P. ("Claremount VII"). Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the securities held by Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 16:05 UTC | Oscar Health, Inc. OSCR · Entity 3582 | Grant7.25% Convertible Senior Notes · Derivative | 34,583,000 | $34,583,000.00 Strike: $8.32 | $1,195,983,889,000,000.00 |
DisclosureSEC source: 0000899243-22-005007 · doc4.xml · derivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · Director · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · Director · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · Director · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Thrive Capital Partners VII Growth, L.P. Disclosed balance after: 34,583,000 Underlying: Class A Common Stock · 4,155,911 shares Expires not disclosed F1 · derivative.exercise_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.exercise_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F1 · derivative.expiration_date: The 7.25% Convertible Senior Notes (the "Notes") are governed by an indenture (the "Indenture") between the Issuer and U.S. Bank National Association, as trustee (the "Trustee"). The Notes bear interest at a rate of 7.25% per annum, payable in cash, commencing on June 30, 2022. The Notes may be converted by the holder, subject to certain conditions, at an initial conversion price of approximately $8.32. Before August 31, 2031, holders of the Notes have the right to convert their Notes only upon the occurrence of certain events more fully described in the Indenture. From and after August 31, 2031, holders of the Notes may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the December 31, 2031 maturity date. Upon conversion, the Notes will be settled, at the Issuer's election, in shares of Class A Common Stock, cash, or a combination of cash and shares of Class A Common Stock, F2 · derivative.expiration_date: (Continued from Footnote 1) subject to certain exceptions, including the right of the holder to elect to settle the Notes by Physical Settlement (as defined in the Indenture) upon conversion pursuant to the terms of the Investment Agreement, dated January 27, 2022, between the Issuer and the purchasers of the Notes. The conversion rate and conversion price are subject to customary adjustments upon the occurrence of certain events. Holders of the Notes have the right to require the Issuer to repurchase all or some of their Notes for cash, subject to certain conditions. The Notes are also subject to redemption under certain circumstances and include customary provisions relating to the occurrence of "Events of Default" (as defined in the Indenture). The Notes have a stated maturity of December 31, 2031, subject to earlier conversion, redemption or repurchase in accordance with their terms. F3 · ownership.nature: Securities held directly by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth"). Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Joshua Kushner is the sole managing member of Thrive Partners VII Growth and, in his capacity as managing member, has voting and investment power over the securities held by Thrive VII Growth. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth except to the extent of their pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:39 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 323,725 | $17.86 | $5,780,109.88 |
DisclosureSEC source: 0000899243-21-036299 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,755,222 F3 · shares: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · price: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:39 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 515,344 | $18.10 | $9,326,180.37 |
DisclosureSEC source: 0000899243-21-036299 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,431,497 F1 · shares: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · price: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 18:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 5 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 18:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 18:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 5 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 18:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 18:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 250,000 | $17.50 | $4,375,650.00 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 28, 2021 18:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 250,000 | $17.74 | $4,435,900.00 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 18:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 18:30 UTC Amendment | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 16:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 157,135 | $18.35 | $2,884,165.78 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,843,889 F4 · shares: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · price: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 16:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 160,385 | $18.35 | $2,942,551.52 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,686,754 F3 · shares: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · price: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 16:15 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 167,966 | $17.53 | $2,943,805.71 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,526,369 F1 · shares: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · price: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 19:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 211,703 | $15.43 | $3,267,170.06 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,358,403 F5 · shares: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · price: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 19:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 93,836 | $14.81 | $1,389,861.30 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,146,700 F4 · shares: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · price: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 19:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 55,188 | $15.27 | $842,770.43 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,052,864 F3 · shares: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F3 · price: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 19:56 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 274,697 | $14.68 | $4,033,760.63 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,997,676 F1 · shares: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F1 · price: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 20:32 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 217,590 | $14.05 | $3,057,988.10 |
DisclosureSEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,722,979 F4 · shares: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F4 · price: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:32 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 204,811 | $13.74 | $2,814,819.98 |
DisclosureSEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,505,389 F3 · shares: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F3 · price: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 20:32 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 31,794 | $13.18 | $418,908.21 |
DisclosureSEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,300,578 F1 · shares: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F1 · price: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 24, 2021 Filed Aug 24, 2021 20:43 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 1,074,342 | $12.69 | $13,633,399.98 |
DisclosureSEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,268,784 F4 · shares: Represents (i) 1,061,552 shares purchased by Thrive VII Growth and (ii) 12,790 shares purchased by Claremount VII. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 20:43 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 125,900 | $13.01 | $1,638,009.36 |
DisclosureSEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 194,442 F3 · shares: Represents (i) 124,401 shares purchased by Thrive VII Growth and (ii) 1,499 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. F3 · price: Represents (i) 124,401 shares purchased by Thrive VII Growth and (ii) 1,499 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:43 UTC | Oscar Health, Inc. OSCR · Entity 3582 | PurchaseClass A Common Stock | 68,042 | $13.41 | $912,592.91 |
DisclosureSEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 68,542 F1 · shares: Represents (i) 67,232 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 810 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. F1 · price: Represents (i) 67,232 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 810 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.